Literature DB >> 11599480

Cardiac conduction disturbances in mixed connective tissue disease.

V Rebollar-González, A Torre-Delgadillo, A Orea-Tejeda, V Ochoa-Pérez, R Navarrete-Gaona, E Asensio-Lafuente, J Dorantes-García, R Narváez, A M Rangel-Peña, P Hernández-Reyes, J Oseguera-Moguel.   

Abstract

BACKGROUND: Myocardial involvement occurs in about 20% of patients with mixed connective tissue disease. The purpose of this study was to determine the prevalence of conduction disturbances, their association with other manifestations of the disease.
OBJECTIVE: Determine the prevalence of cardiac conduction disturbances in patients with mixed connective tissue disease attended in an institute in Mexico City and their relation with other manifestations of the disease.
METHODS: One hundred thirteen patients admitted to the Institute with a diagnosis of mixed connective tissue disease were divided into those with conduction disturbances (n = 23) and those without (n = 90). Over a mean follow-up of 10.2 +/- 7.8 years, clinical course, treatment, duration of the disease, types of conduction disturbances and systemic alterations were examined.
RESULTS: There was an overwhelming predominance of women in both groups. Conduction disturbances occurred in about 20% of the patients with mixed connective tissue disease and that was not possible to find significant differences in the outcome of them. As could be expected a significant difference between the two groups was QRS axis, related to anterior hemiblock, the most common conduction alteration observed. During the follow-up one patient death in-group A, but none in group B.
CONCLUSION: Conduction disturbances were present in 20%; in agree with other authors in the literature. However, did not participate in the outcome of the disease.

Entities:  

Mesh:

Year:  2001        PMID: 11599480

Source DB:  PubMed          Journal:  Rev Invest Clin        ISSN: 0034-8376            Impact factor:   1.451


  1 in total

1.  Diastolic function of the heart in mixed connective tissue disease.

Authors:  Judit Végh; Ida Hegedus; Gyula Szegedi; Margit Zeher; Edit Bodolay
Journal:  Clin Rheumatol       Date:  2006-07-25       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.